Ten years ago, if you wanted ketamine treatment for depression, there was one path: find a clinic, sit in an infusion chair, and pay out of pocket for a series of intravenous sessions. For many people that path was closed before it opened — the nearest clinic was three hours away, the cost was prohibitive, or taking six afternoons off work in three weeks simply was not possible.
Today, patients may encounter several different models: IV racemic ketamine in a clinic; FDA-approved intranasal esketamine in a REMS-certified healthcare setting; compounded oral or sublingual racemic ketamine prescribed off-label; and compounded racemic ketamine nasal spray used by some telehealth practices, including the current Vantage model. These are not interchangeable products.
They differ in FDA status, route, pharmacokinetics, monitoring, evidence quality, cost, logistics, and patient selection. The appropriate option is a clinical decision, not simply a convenience preference.
A note on route and formulation. Ketamine evidence is route-specific. Much of the controlled antidepressant literature uses intravenous racemic ketamine, while FDA-approved intranasal esketamine (Spravato®) has its own trial program and REMS requirements. Some real-world telehealth studies involve sublingual ketamine. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. That compounded nasal formulation is not FDA-approved for any psychiatric condition, and route-matched controlled evidence is limited. Results from IV, sublingual, or esketamine studies should not be presented as expected outcomes for compounded nasal ketamine.
The Four Main Pathways
Intravenous ketamine in a clinic. Racemic ketamine administered by infusion, typically 0.5 mg/kg over roughly 40 minutes, in a clinical setting with continuous monitoring of blood pressure, heart rate, and oxygen saturation. This is the route with the longest research history and the largest body of controlled trial data. It is prescribed off-label for depression.
Esketamine (Spravato) nasal spray. The purified S-enantiomer of ketamine, FDA-approved for treatment-resistant depression and, since January 2025, approved as a standalone monotherapy for adults with TRD. Because it is FDA-approved, it is the route most likely to have insurance coverage. It must be administered in a healthcare setting certified under the Spravato REMS program, with at least two hours of post-dose monitoring and a requirement that someone else drive you home.
At-home oral or sublingual racemic ketamine. These compounded formulations are prescribed off-label by some clinicians after evaluation and are used under practice-specific protocols. They are not FDA-approved psychiatric products, and the evidence base is largely observational compared with IV ketamine and esketamine.
Compounded racemic ketamine nasal spray via telehealth. This is the route described in current Vantage materials. It is not Spravato®, is not FDA-approved for any psychiatric condition, and has less route-specific controlled evidence than IV ketamine or FDA-approved esketamine. FDA has previously issued a safety alert specifically concerning compounded ketamine nasal spray.
Bioavailability: The Core Pharmacological Difference
Route changes how quickly and predictably ketamine is absorbed and how much reaches systemic circulation. IV administration is 100% bioavailable by definition and allows precise dosing. Intranasal, sublingual, and oral absorption is lower and more variable. Exact percentages depend on formulation and study conditions and should not be assumed to apply to a compounded product with different concentration, excipients, or delivery device.
For that reason, numerical doses cannot be compared directly across routes. A larger milligram number by an oral, sublingual, or intranasal route does not automatically mean a stronger treatment than a smaller IV dose.
Two practical consequences follow.
Non-IV absorption can be more variable because of mucosal absorption, swallowing, food, individual metabolism, nasal anatomy, spray technique, and formulation. That variability is one reason route-specific evidence and monitoring matter.
What the Evidence Says About At-Home Treatment
The evidence base for telehealth-delivered at-home ketamine is younger than the IV literature, but it is no longer thin.
A 2022 retrospective study of 664 patients receiving at-home sublingual ketamine through a telehealth program reported substantial average reductions in PHQ-9 and GAD-7 scores among treatment completers. Because the study was retrospective, uncontrolled, and specific to sublingual ketamine, it cannot establish equivalence to IV treatment or predict outcomes for compounded intranasal racemic ketamine.
The same study reported frequent transient side effects such as dizziness, loss of balance, and blurred vision. Its findings provide useful real-world information about sublingual home treatment, but they should not be treated as definitive safety evidence for other routes or for unsupervised use.
This is observational evidence, not a randomized comparison. Selection effects, expectation, concomitant care, missing follow-up, and treatment completion can all influence reported outcomes. Head-to-head evidence comparing home compounded formulations with IV ketamine or Spravato remains limited.
Safety Requirements That Make At-Home Treatment Legitimate
At-home use deserves particular safety attention because the patient is not in a clinic during the acute drug effect. FDA has warned that compounded ketamine products can create risks when there is inadequate monitoring for sedation, dissociation, respiratory effects, changes in blood pressure or heart rate, misuse, and other adverse events.
A clinician considering home use should assess psychiatric diagnosis, blood pressure and cardiovascular risk, psychosis or mania history, substance use, current medications, pregnancy status, ability to follow safety instructions, access to help if something goes wrong, and whether the home setting is appropriate. The exact monitoring and support protocol is a clinician and program decision; an article should not invent requirements that may not match Vantage’s actual clinical protocol.
Ketamine is a Schedule III controlled substance. Prescribing should occur within an ongoing clinician-patient relationship that meets federal and state requirements, with clear dosing instructions, follow-up, misuse safeguards, and escalation pathways. FDA has specifically cautioned against compounded ketamine being used without adequate monitoring.
Federal telemedicine rules are time-sensitive. As of September 2026, DEA and HHS have extended qualifying telemedicine flexibilities for prescribing Schedule II-V controlled substances without a prior in-person medical evaluation through December 31, 2026. The rule is temporary, clinicians must still satisfy DEA requirements and state law, and state rules may be more restrictive or require in-person evaluation.
Who Is Better Suited to Each Route
A monitored in-clinic route may be preferred when a clinician wants direct vital-sign observation, more predictable exposure, REMS-based esketamine treatment, closer supervision because of psychiatric or medical risk, or a setting where home possession of a controlled substance is not appropriate.
At-home compounded treatment may be considered for selected patients when the treating clinician determines that telehealth prescribing is lawful, the medical and psychiatric risks are acceptable, the patient can follow the safety plan, and the home environment is appropriate. Convenience alone is not sufficient to establish candidacy.
Factors that may shift care toward an in-person or higher-acuity setting include acute suicidality, psychosis or mania, uncontrolled blood pressure or significant cardiovascular disease, concerning substance-use history, pregnancy, medical complexity, inability to follow the protocol, or lack of an adequately safe environment. These are clinical considerations, not a universal exclusion checklist.
The important point is that screening should be capable of producing a “not appropriate for home treatment” decision when the clinician identifies meaningful risk.
Cost and Access
Cost can differ substantially by route, location, insurance coverage, pharmacy, monitoring requirements, and treatment frequency. Spravato may be covered by insurance for eligible patients because it has FDA-approved indications, while off-label racemic ketamine is often paid directly. Patients should verify actual total-course costs rather than relying on general market rankings.
Insurance coverage and prior-authorization rules vary. HSA or FSA reimbursement also depends on plan rules. Vantage should publish its current program price and payment terms rather than using broad market estimates.
Vantage Telehealth: use current published program pricing and payment options at publication; verify that HSA/FSA language is accurate for the patient’s plan and the service provided.
There is also an equity dimension worth naming. Telehealth can reduce travel barriers for patients in rural areas, people with disabilities, caregivers, and people who cannot repeatedly leave work for clinic visits. At the same time, home treatment presumes reliable technology, a private setting, and whatever safety supports the treating clinician requires. Those resources are not universal. Neither route is automatically more equitable; the relevant barriers differ by patient.
Deciding With a Provider, Not Instead of One
The question in the title of this article cannot honestly be answered by an article. It requires someone to review your diagnosis, treatment history, medications, blood pressure, home circumstances, and support system.
What you can do is arrive informed: know the exact formulation being offered, whether it is FDA-approved or compounded, which route produced the evidence being cited, what monitoring occurs, what happens if you have an adverse reaction, whether an in-person exam is required, and what the full cost will be.
Vantage Telehealth connects users with independent licensed clinicians through Impact Health USA. Current Vantage materials describe clinician-guided compounded racemic ketamine nasal spray. The treating clinician decides whether home treatment is appropriate, whether an in-person evaluation is required, how monitoring will occur, and when an in-clinic or higher-level option is safer.
Learn more about ketamine therapy at Vantage
Frequently Asked Questions
What are the key differences between at-home telehealth ketamine and in-clinic IV infusions?
The main differences are FDA status, route, pharmacokinetics, monitoring, evidence quality, cost, and logistics. IV racemic ketamine has precise dosing and in-clinic monitoring; Spravato is an FDA-approved intranasal esketamine product with REMS requirements; compounded oral, sublingual, and intranasal racemic ketamine are off-label and not FDA-approved psychiatric products. Evidence from one route should not be assumed to apply to another.
Is at-home oral ketamine as effective as intravenous ketamine for depression?
No. Current evidence does not establish that at-home compounded ketamine is equivalent to IV ketamine. A retrospective study of 664 at-home sublingual patients reported substantial symptom improvement, but it lacked a randomized control group and did not study compounded intranasal racemic ketamine. IV ketamine and FDA-approved esketamine have stronger controlled evidence bases.
What safety measures do at-home ketamine programs require?
At-home ketamine requires careful clinician assessment and a clear safety and follow-up plan. Relevant issues include blood pressure and cardiovascular risk, diagnosis, psychosis or mania history, substance use, other medications, pregnancy, ability to follow dosing instructions, home safety, driving restrictions, and what to do if an adverse effect occurs. Exact program requirements vary and should be explained before prescribing.
Who is not a good candidate for at-home ketamine therapy?
Home treatment may be inappropriate when acute psychiatric risk, psychosis or mania, uncontrolled cardiovascular risk, concerning substance use, pregnancy, medical complexity, inability to follow the protocol, or an unsafe home setting raises concern. The treating clinician determines whether home, in-clinic, or higher-level care is appropriate.
How much does at-home ketamine therapy cost compared to in-clinic infusions?
Costs vary substantially. FDA-approved esketamine may have insurance coverage for eligible patients but includes facility monitoring; IV ketamine is commonly direct-pay; compounded at-home programs are also often direct-pay. Patients should compare the full course cost, follow-up and monitoring fees, pharmacy charges, and insurance requirements rather than assuming one route is always cheapest.
What is the process for getting approved for at-home ketamine treatment?
The process generally begins with a clinical evaluation of psychiatric history, prior treatment, current medications, medical conditions, blood pressure and cardiovascular risk, substance use, and home circumstances. The clinician then determines whether prescribing by telehealth is lawful and appropriate, whether an in-person examination is needed, and what monitoring and follow-up are required.
Selected References
• Hassan K, et al. Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: retrospective study of off-label at-home use. Frontiers in Psychiatry. 2022.
• FDA. Potential risks associated with compounded ketamine products for psychiatric disorders. 2023.
• FDA. Potential risks associated with compounded ketamine nasal spray. 2022.
• DEA/HHS. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, through Dec. 31, 2026.
• FDA. Spravato Prescribing Information and REMS requirements.
See how Vantage Telehealth can help — Get Started →
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, treatment, or a recommendation that ketamine is appropriate for any individual. Ketamine is a Schedule III controlled substance. Racemic ketamine is FDA-approved as an anesthetic, not for any psychiatric condition; psychiatric use is off-label. Compounded ketamine products, including compounded racemic ketamine nasal spray, are not FDA-approved or evaluated by FDA for safety, effectiveness, quality, or any psychiatric indication. Spravato® (esketamine) is a distinct FDA-approved product with specific depression-related indications and REMS requirements. Evidence, safety, dosing, and monitoring differ by route and formulation. Federal telemedicine rules for controlled-substance prescribing are time-sensitive and state law may impose additional requirements, including an in-person evaluation. Vantage Telehealth is not a medical provider; it is a technology platform that connects users with independent licensed clinicians through Impact Health USA. All prescribing and clinical decisions are made solely by the treating clinician. Vantage is not an emergency service. For a mental-health crisis or thoughts of suicide or self-harm, call or text 988. For an immediate life-threatening emergency, call 911.